GenVec (GNVC) Gets $590K SBIR Grant from NIAID of NIH
Tweet
Share
E-mailGet Alerts GNVC Hot Sheet
Join SI Premium – FREE
GenVec, Inc. (Nasdaq: GNVC) has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.
The SBIR grant, valued at approximately $590,000, will provide funding to further understand the impact of maternal immunity against RSV on the generation of a protective immune response in newborns. This is an important factor in the development of an effective vaccine for the pediatric population.
The SBIR grant, valued at approximately $590,000, will provide funding to further understand the impact of maternal immunity against RSV on the generation of a protective immune response in newborns. This is an important factor in the development of an effective vaccine for the pediatric population.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Kimbell Royalty closes $221.2M mineral rights acquisition
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
